Epstein-Barr Virus Treatment Guidelines

General Management

The primary treatment for most EBV infections is supportive care, with specific interventions like rituximab reserved for severe complications such as post-transplant lymphoproliferative disorders (PTLD) 1
Management of uncomplicated EBV infections focuses on symptom relief, adequate hydration, and rest until the self-limiting infection resolves 1

All allogeneic hematopoietic stem cell transplant (HSCT) patients and donors should be tested for EBV antibodies before transplantation 1
High-risk patients require prospective monitoring of EBV DNA-emia by quantitative PCR 1
B-cell depletion with prophylactic rituximab might reduce the risk of EBV DNA-emia 2, 3
EBV-specific cytotoxic T lymphocytes (CTLs) should be considered as first-line prophylactic treatment when available 2, 4

Significant EBV DNA-emia without clinical symptoms warrants preemptive therapy with rituximab 4, 5
The recommended regimen is rituximab 375 mg/m² once weekly (1-4 doses) until EBV DNA-emia negativity 4, 1

Rituximab (375 mg/m²) administered once weekly is the treatment of choice for EBV-PTLD, with positive outcomes in approximately 70% of patients 6, 1
Reduction of immunosuppressive therapy should always be combined with rituximab when possible 6, 7
Cellular therapy with donor or third-party EBV-specific CTLs should be considered if available 6, 7

CNS localization of EBV-PTLD requires special consideration due to risk of neurocognitive dysfunction 6, 7
Therapeutic options include rituximab ± chemotherapy based on primary CNS lymphoma protocols 6, 7
Systemic or intrathecal rituximab monotherapy may be used 6, 7
T-cell therapy with EBV-specific CTLs is also an option 6, 7
Radiotherapy may be considered 6, 7

Antiviral drugs (including acyclovir) are ineffective against EBV and should not be used for treatment 2
Reduction of immunosuppression alone is rarely successful for PTLD following HSCT and may increase risk of rejection or GvHD 6, 8
Additional doses of rituximab beyond 4 doses might result in down-regulation of CD20 expression and decreased efficacy 6, 8
Unselected donor lymphocyte infusions can be associated with severe GvHD; previous GvHD is usually a contraindication to DLI 6, 8
EBV-negative B-PTLD presenting late (>5 years) after transplant should be regarded as malignant lymphoma, not PTLD, and treated with appropriate chemotherapy protocols 6, 8

Antiviral agents such as acyclovir, valacyclovir, and ganciclovir have no therapeutic effect against EBV because latently infected B‑cells do not express the viral thymidine‑kinase enzyme required for drug activation. 9

In elderly patients who are immunocompromised (e.g., transplant recipients, those on immunosuppressive drugs, or HIV‑positive), quantitative EBV DNA PCR should be performed on peripheral blood weekly for at least 4 months to detect viral DNA‑emia. 9
When a significant EBV DNA‑emia is identified without clinical symptoms, a pre‑emptive regimen of rituximab (375 mg/m² administered weekly for 1–4 doses) is recommended. 9
Whenever feasible, immunosuppressive therapy should be reduced, and this reduction should be coordinated with rituximab administration. 9

For EBV‑PTLD occurring in the elderly (rare but possible with age‑related immunosenescence), the first‑line therapy is rituximab given at 375 mg/m² once weekly for 1–4 doses until EBV DNA‑emia becomes negative, achieving favorable outcomes in roughly 70 % of patients. 9
Reduction of immunosuppression should accompany rituximab treatment whenever applicable. 9
If available, EBV‑specific cytotoxic T‑cell therapy may be considered as an adjunctive treatment. 9